NO911854L - Fremgangsmaate for fremstilling av peptid-derivater. - Google Patents
Fremgangsmaate for fremstilling av peptid-derivater.Info
- Publication number
- NO911854L NO911854L NO91911854A NO911854A NO911854L NO 911854 L NO911854 L NO 911854L NO 91911854 A NO91911854 A NO 91911854A NO 911854 A NO911854 A NO 911854A NO 911854 L NO911854 L NO 911854L
- Authority
- NO
- Norway
- Prior art keywords
- alkyl
- hydrogen
- optionally substituted
- con
- carboxy
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 12
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- -1 carboxy, carboxy Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 108050009340 Endothelin Proteins 0.000 abstract 1
- 102000002045 Endothelin Human genes 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000005277 alkyl imino group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0217—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -C(=O)-C-N-C(=O)-N-C-C(=O)-
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Det beskrives en fremgangsmåte for fremstilling av peptid- forbindelse med formel (I): -'14 R" RJ R4 CON'' \CON^ \R5 R6 hvor Ri er hydrogen eller acyl, R2 er lavere alkyl, eventuelt substituert ar(lavere)alkyl, cyklo(lavere)alkyl(lavere)alkyl eller eventuelt substituert heterocyklisk(lavere)alkyl, R3 er eventuelt substituert heterocyklisk(lavere)alkyl eller eventuelt substituert ar(lavere)alkyl, R" er hydrogen, eller eventuelt substituert lavere alkyl, R5 er karboksy, beskyttet karboksy, karboksy(lavere)alkyl eller beskyttet karboksyflavere)alkyl, R6 er hydrogen eller eventuelt substituert lavere alkyl, R7 er hydrogen eller lavere alkyl, og A er -O-, -NH-, lavere alkylimino eller lavere alkylen, forutsatt at når R* er (S)-isobutyl, R3 N-(diklorbenzyl- oksykarbonyl)indol-3-ylmetyl, R" er metyl, R5 er metoksykarbonyl, R6 er hydrogen, R7 er hydrogen og A er -NH-, da har den partielle formel ,,3 R3 , den absolutte konfigurasjon - -CON ^CON- eller et salt derav. Forbindelsene kan finne anvendelse ved behandling og forebyggelse av endothelin-medierte sykdommer, så som hypertensjon og lignende.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB909010740A GB9010740D0 (en) | 1990-05-14 | 1990-05-14 | Peptide compounds and their preparation |
GB909026254A GB9026254D0 (en) | 1990-12-03 | 1990-12-03 | Peptide compound and its preparation |
GB919104064A GB9104064D0 (en) | 1991-02-27 | 1991-02-27 | Peptide compound and its preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
NO911854D0 NO911854D0 (no) | 1991-05-13 |
NO911854L true NO911854L (no) | 1991-11-15 |
Family
ID=27265085
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO91911854A NO911854L (no) | 1990-05-14 | 1991-05-13 | Fremgangsmaate for fremstilling av peptid-derivater. |
Country Status (14)
Country | Link |
---|---|
US (1) | US5284828A (no) |
EP (1) | EP0457195B1 (no) |
JP (1) | JPH04244097A (no) |
KR (1) | KR910020030A (no) |
CN (1) | CN1057269A (no) |
AT (1) | ATE165100T1 (no) |
CA (1) | CA2042442A1 (no) |
DE (1) | DE69129248T2 (no) |
FI (1) | FI912328A (no) |
HU (2) | HUT57233A (no) |
IE (1) | IE911620A1 (no) |
NO (1) | NO911854L (no) |
PT (1) | PT97638B (no) |
RU (1) | RU2092491C1 (no) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5514691A (en) * | 1993-05-20 | 1996-05-07 | Immunopharmaceutics, Inc. | N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin |
US5594021A (en) * | 1993-05-20 | 1997-01-14 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin |
US5571821A (en) * | 1993-05-20 | 1996-11-05 | Texas Biotechnology Corporation | Sulfonamides and derivatives thereof that modulate the activity of endothelin |
US5962490A (en) | 1987-09-25 | 1999-10-05 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
US5591761A (en) * | 1993-05-20 | 1997-01-07 | Texas Biotechnology Corporation | Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
US5430022A (en) * | 1990-05-14 | 1995-07-04 | Fujisawa Pharmaceutical Co., Ltd. | Peptide compound and its preparation |
US5614498A (en) * | 1990-06-07 | 1997-03-25 | Banyu Pharmaceutical Co., Ltd. | Endothelin antagonistic substance |
CA2043741C (en) * | 1990-06-07 | 2003-04-01 | Kiyofumi Ishikawa | Endothelin antagonistic peptide derivatives |
US5496928A (en) * | 1990-06-07 | 1996-03-05 | Banyu Pharmaceutical Co., Ltd. | Endothelin antagonistic substance |
US5736509A (en) * | 1990-12-14 | 1998-04-07 | Texas Biotechnology Corporation | Cyclic peptide surface feature mimics of endothelin |
GB9123967D0 (en) * | 1991-11-12 | 1992-01-02 | Fujisawa Pharmaceutical Co | New compound and its preparation |
TW217417B (no) * | 1991-12-04 | 1993-12-11 | Manyu Seiyaku Kk | |
DE69232771T2 (de) * | 1991-12-27 | 2003-01-23 | Kyowa Hakko Kogyo K.K., Tokio/Tokyo | Peptide als antagonisten von endothelin |
US5614497A (en) * | 1991-12-27 | 1997-03-25 | Takeda Chemical Industries, Ltd. | Peptide, production and use thereof |
WO1993023404A1 (en) * | 1992-05-19 | 1993-11-25 | Immunopharmaceutics, Inc. | Compounds that modulate endothelin activity |
US5922681A (en) * | 1992-09-14 | 1999-07-13 | Warner-Lambert Company | Endothelin antagonists |
US5352800A (en) * | 1993-03-11 | 1994-10-04 | Merck & Co., Inc. | Process for the production of a novel endothelin antagonist |
US5401745A (en) * | 1993-03-19 | 1995-03-28 | Merck & Co., Inc. | Quinazolinones substituted with phenoxyphenylacetic acid derivatives |
US5374638A (en) * | 1993-03-19 | 1994-12-20 | Merck & Co., Inc. | Six membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives used to treat asthma |
US5767310A (en) * | 1993-03-19 | 1998-06-16 | Merck & Co., Inc. | Phenoxyphenylacetic acid derivatives |
US5334598A (en) * | 1993-03-19 | 1994-08-02 | Merck & Co., Inc. | Six-membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives |
US5420133A (en) * | 1993-03-19 | 1995-05-30 | Merck & Co., Inc. | Quinazolinones substituted with phenoxyphenylacetic acid derivatives |
CA2121724A1 (en) | 1993-04-21 | 1994-10-22 | Toshifumi Watanabe | Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction |
US6030991A (en) * | 1993-05-20 | 2000-02-29 | Texas Biotechnology Corp. | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
US6613804B2 (en) | 1993-05-20 | 2003-09-02 | Encysive Pharmaceuticals, Inc. | Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
US6342610B2 (en) | 1993-05-20 | 2002-01-29 | Texas Biotechnology Corp. | N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
US6087324A (en) * | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
GB9313330D0 (en) * | 1993-06-28 | 1993-08-11 | Fujisawa Pharmaceutical Co | New compound and its preparation |
US5686478A (en) * | 1993-07-20 | 1997-11-11 | Merck & Co. Inc. | Endothelin antagonists |
US5780498A (en) * | 1993-11-01 | 1998-07-14 | Ciba-Geigy Japan Limited | Endothelin receptor antagonists |
JPH09510720A (ja) * | 1994-03-28 | 1997-10-28 | 日本チバガイギー株式会社 | エンドセリンレセプターのアンタゴニスト |
US5830868A (en) * | 1994-09-13 | 1998-11-03 | Warner-Lambert Company | Substituted DI- and tripeptide inhibitors of protein: farnesyl transferase |
US5559135A (en) * | 1994-09-14 | 1996-09-24 | Merck & Co., Inc. | Endothelin antagonists bearing pyridyl amides |
US5538991A (en) * | 1994-09-14 | 1996-07-23 | Merck & Co., Inc. | Endothelin antagonists bearing 5-membered heterocyclic amides |
US5863902A (en) * | 1995-01-06 | 1999-01-26 | Sibia Neurosciences, Inc. | Methods of treating neurodegenerative disorders using protease inhibitors |
US5804560A (en) * | 1995-01-06 | 1998-09-08 | Sibia Neurosciences, Inc. | Peptide and peptide analog protease inhibitors |
US5977075A (en) * | 1995-04-21 | 1999-11-02 | Novartis Ag | N-aroylamino acid amides as endothelin inhibitors |
CA2229263A1 (en) * | 1995-09-26 | 1997-04-03 | Toshifumi Watanabe | Peptide derivatives, their production and use |
CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
US5977117A (en) * | 1996-01-05 | 1999-11-02 | Texas Biotechnology Corporation | Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin |
US5688499A (en) | 1996-03-13 | 1997-11-18 | Queen's University At Kingston | Antagonism of endothelin actions |
US5958905A (en) * | 1996-03-26 | 1999-09-28 | Texas Biotechnology Corporation | Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin |
US5804585A (en) * | 1996-04-15 | 1998-09-08 | Texas Biotechnology Corporation | Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin |
IL131318A (en) | 1997-04-28 | 2004-08-31 | Encysive Pharmaceuticals Inc | Pharmaceutically acceptable salts of sulfonamides for treatment of endothelin-mediated disorders |
US5783705A (en) | 1997-04-28 | 1998-07-21 | Texas Biotechnology Corporation | Process of preparing alkali metal salys of hydrophobic sulfonamides |
ATE315931T1 (de) * | 1997-06-23 | 2006-02-15 | Cellegy Pharma Inc | Microdosistherapie von gefässbedingten erscheinungen durch no-donoren |
US6998445B2 (en) * | 1998-03-26 | 2006-02-14 | Acushnet Company | Low compression, resilient golf balls with rubber core |
AU4572999A (en) * | 1998-06-18 | 2000-01-05 | Sepracor, Inc. | Tetrapeptides, analogs and peptidomimetics which bind selectively mammalian opioid receptors |
US7115664B2 (en) * | 2000-03-16 | 2006-10-03 | Sepracor Inc. | Peptidomimetic ligands for cellular receptors and ion channels |
EP2168980A1 (en) | 2000-06-23 | 2010-03-31 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogensis |
EP2042597B1 (en) | 2000-06-23 | 2014-05-07 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
WO2002043709A1 (fr) | 2000-12-01 | 2002-06-06 | Takeda Chemical Industries, Ltd. | Procede de production d'une preparation contenant une substance bioactive |
ATE447955T1 (de) * | 2001-08-24 | 2009-11-15 | Univ Yale | Piperazinon-verbindungen als antitumorale und krebsbekämpfende mittel |
GB0326632D0 (en) | 2003-11-14 | 2003-12-17 | Jagotec Ag | Dry powder formulations |
ATE495752T1 (de) | 2005-07-19 | 2011-02-15 | Population Council Inc | Verfahren und zusammensetzungen zur notfallbedingten verhütung mithilfe von endothelin-rezeptor-antagonisten |
WO2012028745A1 (en) | 2010-09-03 | 2012-03-08 | Pharmaterials Limited | Pharmaceutical composition suitable for use in a dry powder inhaler |
MY172013A (en) | 2011-10-26 | 2019-11-12 | Allergan Inc | Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 (fprl-1) receptor modulators |
US20150157619A1 (en) | 2012-07-10 | 2015-06-11 | Takeda Pharmaceutical Company Limited | Pharmaceutical preparation for injection |
KR102313757B1 (ko) * | 2013-07-16 | 2021-10-18 | 알러간, 인코포레이티드 | 펩타이드 수용체 조절제로서의 n-우레아 치환된 아미노산의 유도체 |
SI3464336T1 (sl) | 2016-06-01 | 2022-06-30 | Athira Pharma, Inc. | Spojine |
EP4308170A1 (en) | 2021-03-18 | 2024-01-24 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1049404B (it) * | 1975-04-09 | 1981-01-20 | Zambeletti Spa L | Tripeptidi loro esteri ed amidi ad attivita antiulcera |
US4127534A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel tripeptides, intermediates therefor and pharmaceutical compositions and methods employing said tripeptides |
US4228156A (en) * | 1979-03-30 | 1980-10-14 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
CA1175810A (en) * | 1979-03-30 | 1984-10-09 | Frank A. Momany | Synthetic peptides having pituitary growth hormone releasing activity |
GB8430255D0 (en) * | 1984-11-30 | 1985-01-09 | Erba Farmitalia | Biologically active oligopeptides |
US5187156A (en) * | 1988-03-16 | 1993-02-16 | Fujisawa Pharmaceutical Co., Ltd. | Peptide compounds, processes for preparation thereof and pharmaceutical composition comprising the same |
CA2043741C (en) * | 1990-06-07 | 2003-04-01 | Kiyofumi Ishikawa | Endothelin antagonistic peptide derivatives |
-
1991
- 1991-05-07 US US07/696,701 patent/US5284828A/en not_active Expired - Fee Related
- 1991-05-09 DE DE69129248T patent/DE69129248T2/de not_active Expired - Fee Related
- 1991-05-09 AT AT91107554T patent/ATE165100T1/de not_active IP Right Cessation
- 1991-05-09 EP EP91107554A patent/EP0457195B1/en not_active Expired - Lifetime
- 1991-05-10 IE IE162091A patent/IE911620A1/en unknown
- 1991-05-10 PT PT97638A patent/PT97638B/pt not_active IP Right Cessation
- 1991-05-13 FI FI912328A patent/FI912328A/fi not_active Application Discontinuation
- 1991-05-13 CN CN91103919A patent/CN1057269A/zh active Pending
- 1991-05-13 CA CA002042442A patent/CA2042442A1/en not_active Abandoned
- 1991-05-13 NO NO91911854A patent/NO911854L/no unknown
- 1991-05-13 KR KR1019910007647A patent/KR910020030A/ko not_active Application Discontinuation
- 1991-05-13 RU SU914895608A patent/RU2092491C1/ru active
- 1991-05-14 HU HU911619A patent/HUT57233A/hu unknown
- 1991-05-14 JP JP3206614A patent/JPH04244097A/ja active Pending
-
1995
- 1995-06-22 HU HU95P/P00377P patent/HU211904A9/hu unknown
Also Published As
Publication number | Publication date |
---|---|
DE69129248T2 (de) | 1998-08-06 |
AU7644691A (en) | 1991-11-14 |
DE69129248D1 (de) | 1998-05-20 |
KR910020030A (ko) | 1991-12-19 |
RU2092491C1 (ru) | 1997-10-10 |
AU644648B2 (en) | 1993-12-16 |
NO911854D0 (no) | 1991-05-13 |
EP0457195A2 (en) | 1991-11-21 |
PT97638B (pt) | 1998-08-31 |
HU211904A9 (en) | 1996-01-29 |
EP0457195B1 (en) | 1998-04-15 |
EP0457195A3 (en) | 1992-11-19 |
IE911620A1 (en) | 1991-11-20 |
PT97638A (pt) | 1992-02-28 |
FI912328A (fi) | 1991-11-15 |
HUT57233A (en) | 1991-11-28 |
CA2042442A1 (en) | 1991-11-15 |
JPH04244097A (ja) | 1992-09-01 |
US5284828A (en) | 1994-02-08 |
CN1057269A (zh) | 1991-12-25 |
FI912328A0 (fi) | 1991-05-13 |
ATE165100T1 (de) | 1998-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO911854L (no) | Fremgangsmaate for fremstilling av peptid-derivater. | |
MX9401408A (es) | Nuevos derivados heterociclicos. | |
DE69327541D1 (en) | 4-arylmethyloxymethyl piperidine als tachykinin antagonisten | |
YU9301A (sh) | Peptidi kao inhibitori hepatitisa c | |
DE69315079D1 (de) | Beta-aminoalkyl und beta-n-peptidylaminoalkylborsäure | |
CA2078790A1 (en) | 3-benzylidene-1-carbamoyl-2-pyrrolidone analogues | |
DK0736018T3 (da) | 4,5-Diaryloxazolderivater | |
GB9602029D0 (en) | New heterocyclic compounds | |
DE69433984D1 (de) | Arylpiperazinderivate von indol als liganden der rezeptoren 5 ht1-like, 5 ht1b und 5 ht1d | |
ES2091359T3 (es) | Nuevo compuesto peptidico y un procedimiento para su preparacion. | |
ATE254121T1 (de) | Heterocyclische verbindungen als bradykinin antagonisten | |
NO20031671L (no) | Dioksolananaloger for forbedret intercellulaer avlevering | |
FI913614A (fi) | Menetelmä terapeuttisesti käyttökelpoisten N-sulfonyyli-indoliinijohdannaisten valmistamiseksi | |
ES2141827T3 (es) | Peptidos que tienen actividad antagonista de endotelina, su preparacion y composiciones farmaceuticas de los mismos. | |
NO973340L (no) | Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for behandling eller profylakse av fedme | |
SE9603285D0 (sv) | New compounds | |
ATE137764T1 (de) | Vasoaktive derivate des vasotocins | |
PT827500E (pt) | Derivados de (2-morfolinilmetil)benzamida | |
FI930166A (fi) | Nya salter av dialkylaminoalkyl-26-sulfonylpristinamycin iib-derivat | |
WO2001007468A3 (en) | Novel cyclohexapeptide compounds, processes for their production and their use as a pharmaceutical | |
NO962809L (no) | Fremgangsmåte for fremstilling av N-substituerte 4-ketoprolinderivater |